The AJMC® Ophthalmology compendium is a comprehensive resource for clinical news and expert insights for treatment of disorders of the eye.
July 18th 2025
The symptoms of dry eye are multifactorial, says Mina Massaro-Giordano, MD, making identifying and treating dry eye important for quality of life.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Evolving Strategies for Managing nAMD and DME: Empowering Managed Care Decisions for Improved Patient Outcomes
1.5 Credits / Endocrinology, Diabetes & Metabolism, Ophthalmology/Optometry
View More
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
View More
Harnessing Data-Driven Insights and Innovations to Enhance AMD and DME Management: Strategic Approaches for Managed Care
1.5 Credits / Ophthalmology/Optometry
View More
Advancing Care in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Optimizing Outcomes With Emerging Therapies
1.5 Credits / Ophthalmology/Optometry
View More
Leveraging Novel Therapies to Transform Demodex Blepharitis Care (Pharmacy Technician Credit)
1.5 Credit / Ophthalmology/Optometry
View More
Leveraging Novel Therapies to Transform Demodex Blepharitis Care
1.5 Credit / Ophthalmology/Optometry
View More
Intravitreal Faricimab Associated With Increased Treatment Interval, Decreased CST
December 23rd 2024Although intravitreal faricimab helped to decrease central subfield thickness (CST) in patients with eyes previously treated for neovascular age-related macular degeneration, best corrected visual acuity showed no sign of improvement.
Read More
Visual Acuity, OSDI Improved With Use of Hydrogen Peroxide in Dry Eye Caused by Contacts
December 11th 2024Patients with dry eye associated with contact lenses had significant improvement in visual acuity and their Ocular Surface Disease Index (OSDI) score after a month of using hydrogen peroxide.
Read More
Atsena Therapeutics and Nippon Shinyaku Enter Exclusive License Agreement for ATSN-101
November 13th 2024Atsena Therapeutics and Nippon Shinyaku have formed an exclusive licensing agreement for ATSN-101, a gene therapy for Leber congenital amaurosis (LCA1). Nippon Shinyaku will commercialize ATSN-101 in the US and Japan, while Atsena retains global rights outside these territories.
Read More